Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：36
|
作者：
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles Galceran, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Gustave Roussy Canc Campus, Villejuif, France
[3] Univ Paris Sud, Villejuif, France
[4] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[5] Univ Wollongong, Wollongong, NSW, Australia
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Acad Hosp Braunschweig, Braunschweig, Germany
[8] Auckland City Hosp, Auckland, New Zealand
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[11] UCL, Inst Canc, London, England
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Inst Curie, Paris, France
[14] Klinikum Nurnberg, Nurnberg, Germany
[15] Catalan Canc Inst, Barcelona, Spain
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
145
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [32] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [33] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
    Petrylak, Daniel Peter
    Shore, Neal D.
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep M.
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [35] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Goh, Jeffrey C. H.
    Ojamaa, Kristiina
    Rodriguez, Jose Maria Piulats
    Drake, Charles G.
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Linch, M.
    Ferrario, C.
    Stoeckle, M.
    Laguerre, B.
    Arija, J. A. Arranz
    Todenhofer, T.
    Fong, P. C.
    Rodriguez, J. M. Piulats
    Berry, W.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
  • [38] Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
    Schmidt, Andrew Lachlan
    Anton, Angelyn
    Wong, Shirley S.
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia Anne
    Torres, Javier
    Muthusamy, Arunbalaji
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey C.
    Joshua, Anthony M.
    Pook, David William
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
    Appleman, Leonard
    Todenhoefer, Tilman
    Berry, William
    Gurney, Howard
    Retz, Margitta
    Conter, Henry
    Laguerre, Brigitte
    Fong, Peter
    Ferrario, Cristiano
    Gravis, Gwenaelle
    Piulats, Josep
    Emmenegger, Urban
    Shore, Neal
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
  • [40] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
12345